Q3 was released a few days ago: Investor Relations
Still seems expensive. Growth has stumbled a bit this year. It would be interesting to know more precisely why, and whether the problems are temporary.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Acarix - Sepelvaltimotaudin seulontaa | 7 | 2840 | December 6, 2021 | |
| IDEXX Laboratories – Eläinterveyden edistäjä | 11 | 1269 | February 2, 2026 | |
| Nordhealth AS - Suomalaista SaaSia Norjasta | 1 | 2293 | July 12, 2021 | |
| Securitas - turvallisuuspalveluyritys Tukholman pörssistä | 7 | 3161 | February 6, 2026 | |
| Enovix - Tulevaisuuden akkuteknologiaa | 7 | 920 | May 16, 2026 |